Participation in a clinical trial is an important element of healthcare, especially for patients with life-threatening and/or rare diseases for whom a medicinal product under investigation might be the only therapeutic option.
As there is no legal EU framework that defines the conditions for accessing clinical trials in another EU member state, there is need for reliable and accessible information regarding practical aspects, as well as for multi-stakeholder, multi-national recommendations on existing options and best practice for patients, investigators and trial sponsors on conditions and options for cross-border access to clinical trials.
EFGCP and EFPIA have set up a multi-stakeholder consortium of patient organisations, academics, research networks, industry and not-for-profit organisations with the aim to systematically collect available information from all European countries and to develop recommendations for enabling cross-border access to clinical trials: the EU Cross-border Trials Initiative called EU-x-CT.
EU-X-CT
Cross-border Access to Clinical Trials Initiative
for articles/videos/studies
Healthcare professionals who wish to be part of a unique network, providing access to up-to-date, accurate and validated information about clinical research.
Investigators and study staff who wish to be part of a unique network, in order to stay abreast of clinical trials taking place in Luxembourg and who are willing to further develop their competencies.
